SODIUM-GLUCOSE TRANSPORTER 2 (SGLT2)
Steglatro is a prescription drug approved by the Food and Drug Administration (FDA) to help improve blood glucose control in adults with type 2 diabetes. Steglatro is considered an adjunct treatment to diet and exercise. Steglatro is also referred to by its drug name, Ertugliflozin.
Steglatro is a sodium-glucose transporter 2 (SGLT2). Steglatro is believed to work by causing excess glucose to be eliminated in the urine.
How do I take it?
Prescribing information states that Steglatro is taken once daily in the morning, with or without food.
Steglatro comes in tablet form.
The FDA-approved label for Steglatro lists yeast infections in women as a common side effect.
Rare but serious side effects listed for Steglatro include hypoglycemia (low blood glucose), kidney problems, and urinary tract infections.
For more details about this treatment, visit:
Steglatro.com – Merck
What Are My Options? – American Diabetes Association